KRAS and neoplasm: Combining the KRAS and TP53 double-mutated tumor phenotype with the abovementioned lymph-nodal stage at the time of surgery, we observed a dramatic prognosis in the double-mutated PDAC patients with an N2 stage compared to all the other patients (wild-type phenotype or tumors harboring just one mutation, without lymph-nodal spread, N0, or with limited ones, N1) (Figure 4).